LGALS9 and neoplasm: Moreover, the blockade of Gal-9 can potentially enhance the efficacy of other immunotherapeutic agents, such as PD-(L)1 and CTLA-4 inhibitors, by relieving the suppression of immune cell activity within the tumor microenvironment.